Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics-Reference-Cited by-同舟云学术

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics

Published:2018-02 Issue: Volume:271 Page:127-138
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Sims Jessica D.,Taguiam Jan Michael,Alonso-Valenteen Felix,Markman Janet,Agadjanian Hasmik,Chu David,Lubow Jay,Abrol Ravinder,Srinivas Dustin,Jain Anjali,Han Bingchen,Qu Ying,Mirzadehgan Parisa,Hwang Jae-Youn,Rentsendorj Altan,Chung Alice,Lester Jenny,Karlan Beth Y.,Gray Harry B.,Gross Zeev,Giuliano Armando,Cui Xiaojiang,Medina-Kauwe Lali K.

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference45 articles.

1. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase;Garrett;Proc. Natl. Acad. Sci.,2011

2. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function;Garrett;Clin. Cancer Res.,2013

3. Expression and nuclear localization of ErbB3 in prostate cancer;Koumakpayi;Clin. Cancer Res.,2006

4. Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block;Jathal;Immunol. Endoc. Metab. Agents Med. Chem.,2011

5. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer;Zhang;World J. Surg.,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human Blood Serum Antagonizes Effects of EGFR/HER2-Targeted Drug Lapatinib on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Биохимия;2024-09-14

2. Human Blood Serum Counteracts EGFR/HER2-Targeted Drug Lapatinib Impact on Squamous Carcinoma SK-BR-3 Cell Growth and Gene Expression;Biochemistry (Moscow);2024-03

3. Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors;Cancers;2023-06-19

4. Milestones in corrole chemistry: historical ligand syntheses and post-functionalization;Chemical Society Reviews;2023

5. HER3 in cancer: from the bench to the bedside;Journal of Experimental & Clinical Cancer Research;2022-10-21